Injection Site Reaction
Conditions
Brief summary
The objective of this study is to identify and assess in vivo tissue responses after injection with various biostimulatory products at various timepoints. The study will also provide tissue specimens which will be used in a subsequent study. Safety endpoint: incidence of adverse events.
Detailed description
The objective of this study is to identify and assess tissue responses after injection with various biostimulatory products that are already used in the market and have CE approval. The study will assess in vivo tissue responses and provide tissue specimens which will be used in a subsequent study, under a separate protocol. Assessments under this protocol will include ultrasound of in vivo tissue. Safety endpoint: incidence of adverse events.
Interventions
DEVICEInjection
A pre specified amount will be injected in tissue at selected timepoints
Sponsors
Merz North America, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Injections will be in redundant abdominal tissue scheduled to be removed at end of study
Eligibility
Sex/Gender
ALL
Age
22 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male & females; 22 to 65 years of age. 2. Voluntary participation 3. Ability to comprehend and provide informed consent. 4. Participants agree NOT to use any topical agents or products that will induce skin peeling or change the appearance of the skin in the treatment area, during the study period. 5. Participants agree NOT to undergo any aesthetic treatments that influence the appearance of the skin in the treatment area during the study period. 6. Participants agree NOT to undergo any surgical treatments in the treatment area during the study period. 7. Participants agree NOT to take part in another clinical study or undergo other treatments during the study period.
Exclusion criteria
1. Any previous surgery in the abdominal area. 2. Any previous treatment in the abdominal area. 3. Planning to receive treatment of any kind in the abdominal area. 4. Acute inflammatory process and/or infection at the injection site. 5. Treatment of skin area with dermatosis. 6. Eczema, exanthema or open wounds. 7. Previous application of over the counter or prescription, oral or topical, anti-wrinkle or skin enhancer products on the abdominal skin within the past 3 months unless allowed by the study and is continued throughout the study. 8. Any contraindication to treatment with biostimulatory products based on the product's IFU. 9. Previous pregnancy or intending to become pregnant during study participation. 10. Known hypersensitivity to biostimulatory products or any of their formulation ingredients. 11. Allergic reaction to topical and local anesthetics. 12. Currently using anticoagulant therapy. 13. Haemophilia / bleeding disorder. 14. Chemotherapy, radiotherapy or high doses of corticosteroids. 15. Systemic infection (e.g., hepatitis). 16. Uncontrolled diabetes mellitus. 17. Any medical condition that may put the participant at increased risk with exposure to biostimulatory products. 18. Any medication that might modulate the immune response. 19. Any other illness or condition that, in the opinion of the investigator, would mean that study participation was not in the best interest of the prospective participant. 20. Is a female of childbearing potential and not using medically effective birth control or is pregnant or lactating. 21. Any serious disease or disorder (medical or psychiatric) that could, in the opinion of the investigator, interfere with the safe completion of treatment according to this protocol or with study. 22. Injection of local anesthesia into the flap during abdominoplasty surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ultrasound Analyses | 6 months, 3 months and 2 weeks prior to surgery timepoint(s) | Ultrasound of injection site tissue analyses (dermal thickness (mm), elastosis (mm) and microvascular formation) by PI at various timepoints |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety Assessment | through study completion, an average of 6 months | Adverse event reporting |
Countries
Spain
Outcome results
None listed